is believed as one of therapeutic strategies of CD. This study is dedicated to identify predictors of response to EN in CD, which may lead to a better selection of fistula patients for this therapy. SUBJECTS/METHODS: Forty-eight CD patients with ECF treated with short-peptide-based EN for 3 months were included in this study. All patients were followed up for at least 6 months. Logistic regression was performed to investigate the potential predictors of response to EN in these patients. RESULTS: In total, 30 out of 48 patients were confirmed with a successful closure of fistula after 3 months' EN therapy. The average closure time was 32.4 ± 8.85 days. Inflammatory parameters (erythrocyte sedimentation rate, C-reactive protein (CRP) and platelet count) improved significantly after EN therapy in all enrolled patients. Specifically, the improvement of CRP after therapy in closed group was more important compared with that in unclosed group (P = 0.035). Nutrition status (body weight, body mass index (BMI), hemoglobin, serum albumin (ALB), serum prealbumin and total protein (TP)) improved as well (P o0.05). Similarly, after treatment, the improvement of serum albumin (P = 0.046) and prealbumin (P = 0.006) in closed group was much more important than those in unclosed group. Logistic regression analysis discovered that a decreased CRP level and an elevated BMI level would be beneficial to the response to EN in CD patients with ECF. CONCLUSIONS: In CD patients with ECF, lower CRP and higher BMI are associated with higher possibility of closure after EN treatment. EN therapy can lead to a closure of ECF in a certain proportion of patients. EN therapy could also ameliorate inflammatory condition and improve nutrition status.
INTRODUCTION
Crohn's disease (CD) is a chronic, transmural, inflammatory disease of the gastrointestinal tract with unknown etiology. The nature of idiopathic transmural inflammation of CD can lead to severe complications, including fistulas, abscesses and intestinal obstruction. In population-based cohorts, the cumulative incidence of fistula is 17-50%. 1 Another study showed a cumulative incidence of fistula in CD as 33% after 10 years and 50% after 20 years. 2 Meanwhile, therapeutic strategies to fistula are still limited. 3 As fistula may lead to imbalance of fluid and electrolytes, severe infection, malnutrition and thereby a decrease of quality of life, 4 it becomes a challenge for clinical doctors.
In recent years, immunosuppressants, especially biological agents are widely adopted in the management of CD. Nevertheless, enteral nutrition (EN) remains of interests in patients presenting concomitant malnutrition (a common complication in CD), intolerance or failure to other therapeutics. 5 Even in remission, CD patients encounter micronutrient deficiencies frequently. 6 Therefore, EN has been recognized as unique advantages in adult CD patients to achieve and maintain clinical remission or correct nutritional disturbances. 7, 8 EN is also a therapeutic alternative for patients who suffer severe side effects to other therapies.
In our clinical practice, EN is adopted in the management of CD patients with enterocutaneous fistula (ECF). The purpose of this study was to evaluate potential predictors of responses to EN in CD patients with ECF.
METHODS
From May 2007 to March 2012, 135 CD patients with a diagnosis of ECF in our center were initially enrolled in this study (Figure 1 ). The exclusion criteria included withdrawal from EN therapy, upcoming operations in the next 3 months, biological therapies or corticosteroids in previous 8 weeks, intestinal stenosis and serious infection. Intestinal-visceral fistula and intestinal-intestinal fistula were excluded as well. Among the excluded patients, 27 patients were assigned to an operation during the study period because of significantly reduced intra-abdominal adhesion. Another 26 patients had internal fistula, 12 patients had intestinal stenosis, 14 patients showed high output (>200 ml/24 h) and 8 patients died during study period mainly due to severe intra-abdominal infection. A total of 48 eligible CD patients with ECF (mean age 30.379.2 years, range 18-70) (Table 1) were finally enrolled in current study, which included 40 postoperative fistula and 8 spontaneous fistula.
Management and assessment
On enrollment, inflammatory parameters (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and platelet count) and nutritional indicators (body mass index (BMI), hemoglobin, serum albumin (ALB), serum prealbumin (PALB), total protein) were collected. Fistula diagnosis was made with fistula imaging and computed tomography; fluid and electrolytes abnormalities were corrected. Abdominal fluid collections and abscesses were treated with dual-lumen-tube suction drainage. After infection was controlled and internal environment homeostasis was obtained, all patients received short-peptide-based EN (30 Kcal/kg per day) provided by continuous infusion through a nasogastric feeding tube for 3 months. These patients that were receiving EN therapy were strictly forbidden to eat anything else. Only normal saline might be supplemented to maintain water and electrolytes balance when necessary. Meanwhile, these patients received 5-aminosalicylic acid or immunosuppressive therapy just as before. A closed fistula was defined as a covering by skin for at least 2 weeks. After 3 months' EN therapy, the inflammatory and nutritional parameters were collected again. All patients were followed up for at least 6 months after EN therapy.
Statistical analysis
Statistical analysis was carried out using the software SPSS (SPSS 17.0, Nanjing, China). Quantitative data were expressed as mean ± s.d. Comparisons between groups were conducted using Student's t-test or Χ 2 -test. Logistic regression analysis was performed to investigate the potential predictors of response to EN. The independent parameters included CRP, ESR, platelet count, hemoglobin, ALB, PALB, BMI and location of fistula; the dependent index was the outcome of ECF (closed or not). Kaplan-Meier analysis was performed to describe the interval between fistula closure and subsequent reopening. Results were considered significant when Po 0.05.
RESULTS
After 3 months' EN treatment, 30 patients (62.5%) obtained a successful closure of fistula within an average time of 32.4 ± 8.85 days ( Figure 2 ). Specifically, 24 of 40 postoperative fistula and six of eight spontaneous fistula closed within 34.1 ± 8.7 days and 25.5 ± 5.6 days, respectively. Among all 30 patients who obtained closure of fistula, eight patients relapsed on 3, 6, 10, 11, 13, 26, 33, 44 months after closure, respectively ( Figure 3 ). All of these eight patients received a bowel resection surgery after relapse. One patient with ileocolic anastomotic fistula was closed by 3 months' EN therapy (Figure 4 ). Closure rate in small intestinal fistula (16/23, 69.6%) was slightly higher than colonic fistulas (9/14, 64.3%) and ileocolic anastomotic fistulas (5/11, 45.5%). However, the differences of closure rates did not reach statistical significance. Figure 1 . A flow chart began with the initial population who began EN for CD and showed how many patients were excluded and the reasons for that. Figure 2 . These fistula patients of CD were treated by semielemental nutrition for 3 months. Part of these patients' fistula got closed during therapy. The full line gives the shape of percentage increase on fistula closed patients, whereas the dotted line represents the 95% confidence interval. Before EN treatment, ESR and platelet count were similar between closed and unclosed groups. However, CRP was statistically lower in closed group than that in unclosed group (P = 0.035). After EN treatment, all three inflammatory parameters (ESR, platelet count and CRP) were significantly decreased in both the groups (Table 2) .
The nutrition status of these fistula patients got much improvement after EN therapy. There was significant increase on body weight and BMI after treatment (Table 3 ). Nutritional improvement of the patients considered as a whole was obviously on hemoglobin, serum albumin, prealbumin concentration and serum total protein ( Table 3 ). The mean hemoglobin of unclosed group increased from 103.2+18.5 g/dl to 109.7 ± 13.5 g/dl (P = 0.075) after treatment, Whereas the closed group was increased greatly (Po 0.001). Serum albumin, PALB level and serum total protein also significantly increased after nutritional therapy compared with the value before treatment in both closed and unclosed group (P o 0.05). Nevertheless, there was no significant difference between the two subgroups on changes of hemoglobin and serum total protein except for serum albumin (P = 0.046) and PALB (P = 0.006).
Logistic regression analysis was used to assess the correlation between clinical variables and treatment outcome. Logistic regression analysis suggested that patients with lower CRP (P = 0.003 odds ratio: 26.6, 95% confidence interval: 2.98-237.5) and higher BMI (P = 0.037, odds ratio: 12.66, 95% confidence interval: 1.16-138.0) may have a higher possibility of fistula closure after EN treatment.
Except for mild diarrhea (29.2%), nosebleeding (one patient) and pharyngitis (one patient), there was no serious adverse events reported in all eligible patients.
DISCUSSION
The initial reports evaluating the effectiveness of EN in the management of CD emerged in the late 1960s, with a primary goal of improving nutrition status. 9, 10 Later on, studies showed that EN could also exert anti-inflammatory effects. 11 Preoperative weight loss, prolonged refractory symptoms and penetrating disease behavior are significant determinants of postoperative complication risk. Preoperative EN, antibiotics, percutaneous abscess drainage and cessation of steroids might reduce the risk of surgery. 12 Early nutritional support, independently of the route of administration, decreases the occurrence of fistulae.
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In this study, 30 out of 48 CD patients achieved fistula closure after 3 months' EN therapy. The short-peptide-based EN might induce disease remission with the reduction of bowel inflammation, promote digestion and absorption to correct malnutrition states, and reduce the fistula output. Both low residue and prebiotic properties of EN may be the mechanism of EN on modification of gut microflora.
14 All of these reasons above might promote the closure of fistula.
Another report showed that nonsurgical and primary surgical management strategies result in similar rates of abscess recurrence and complications among CD patients with intra-abdominal abscesses. 15 That study also confirmed the validity of conservative treatment on surgical complications. Nevertheless, perianal fistula were excluded from our study.
Our study displayed a difference of closure rate in different fistula locations. Though there was no statistical significance, the data suggested that the ileocolic anastomotic fistula was more difficult to be closed than that in the small intestine and colon. The high closure rate of small intestine fistula may be due to the much more sufficient supply of blood in small intestine. In total, 10 of these 14 colonic fistula patients received previous appendectomy with less destruction of blood supply, which might contribute to the high closure rate of colonic fistula in current study. The low-closure rate of ileocolic anastomotic fistula could be influenced by ileocecal valve excision, which may result in bacteria extended upward. There might be other factors which affect the closure of fistula, including the degree of local inflammation, the nutrition status, the time and efficacy of fistula drainage. While the recurrence rate of fistula in our study was significantly lower than that in Yamazaki's report, 16 we assumed that the relapse of fistula may induced by the relapsed of CD.
EN is effective in inducing remission of CD, but certain patients relapsed quickly after resumption of a normal diet. 17 This result further validated that EN may be useful for maintaining remission. 8 These patients were followed up routinely and would be prescribed therapeutic intervention accordingly to decrease the risk of recurrence.
Although the exact etiologies of CD remain uncertain, results from research have provided important new insights into the pathogenesis of chronic, immune-mediated, intestinal inflammation. 18 In this study, the closed fistula treated by EN might attribute to the reduction of intestinal inflammation. ESR, CRP and platelet count were significantly improved after EN therapy. However, these serum parameters might not reflect the Enteral nutrition therapy for crohn's abdominal fistula D Yan et al local inflammation status accurately, which may explain that there was not significant difference between patients in the fistula closed group and the unclosed group. For the treatment of CD in children and adolescents, enteral feeding with a semi-elemental diet seems to be as effective as corticosteroids in inducing remission. 19 Bowel rest and induction of anabolism mechanisms may both contribute to the effectiveness of EN therapy. 20 EN may modulate gut inflammation by directly reducing the inflammatory response of the intestinal epithelium 21 or by modulating intestinal bacteria. 22 It can also result in mucosal healing and a down regulation of mucosal pro-inflammatory cytokine. 23 Glutamine preserved both extraintestinal and intestinal IgA levels and had a normalizing effect on Th2-type IgA-stimulating cytokines. 24 Fat content has also been considered as a potential source of the clinical benefits of EN. Fat of different types may interact with cytokine genotype, modulating disease activity, 23, 25 such as low intake of n-3 polyunsaturated fatty acid and high n-6/n-3 polyunsaturated fatty acid ratio in patients with the TN-α polymorphism were associated with higher disease activity in CD. The increased number of platelets represents a significant risk factor for amplification of gut inflammation. 26 Although these patients received medical antiinflammatory therapy as before, neither 5-aminosalicylic acid nor immunosuppressive therapy were effective in preventing quiescent CD relapse, 27, 28 nor their usage could prevent the the occurrence of fistula before therapy.
Because of malabsorption, metabolic disturbances and fistula leakage, malnutrition is frequent in these patients. Patients with active CD are at high risks of protein-energy malnutrition, with a prevalence ranging up to 75%. 29 The management of ECF in CD is a complex, great challenge with recurrence or further complications, unless the nutritional state is optimized. However, EN therapy can effectively reduce the undesirable consequences by improving nutrition status assessed by hemoglobin, serum total protein, serum albumin and PALB. A single treatment of EN might not be enough to treat anemia because anemia in patients with CD are most likely not secondary to diet. 30 Proinflammatory cytokines produced in inflammatory bowel disease can suppress erythropoiesis by the inhibition of erythropoietin secretion and action. 31 There were also many reasons contributing to anemia of IBD, such as chronic intestinal blood loss through ulcerations, extensive ileal resection, chronic intestinal inflammation 32 and iron deficiency. 33 EN therapy not only improves the nutritional status, but also ameliorates intestinal adhesion, reduces serum levels of inflammatory markers, 34 minimizes the risk of postoperative complications. 35 The logistic regression analysis indicated that low CRP and high BMI might be the predictors of response to EN in abdominal fistula patients with CD. EN treatment might have an essential role in facilitating the closure of fistula.
EN therapy in CD could facilitate closure of fistula, reduce inflammatory parameters and improve nutrition status. Our data suggested that semi-elemental EN therapy is a good choice for CD patients with ECF.
